News
News from us and our partners
News
News
Crossover
News
News
Industrial Biotech
News
Capital
News
Digital Medicine
News
Sofinnova Partners raises €1.2 billion to fuel the next wave of life sciences innovation
CEO spotlight: Thierry Abribat's third straight win
Sofinnova’s newest partners discuss their career paths
Sofinnova publishes 2023 Impact Report
Johnson & Johnson to acquire Shockwave Medical
Cure51 raises €15 million to harness the power of cancer survivors
CEO spotlight: CinCor's Marc de Garidel
Tags
Topics
0 results
- News
T-Therapeutics appoints Theodora Harold as Chief Executive Officer, reflecting Company’s ambitious growth plans and progression into therapeutic development
- News
Sofinnova Partners raises €1.2 billion to fuel the next wave of life sciences innovation
- News
Pi-Cardia Reports First Commercial Cases with ShortCut™
- Feature
Healthcare in the post-COVID era, where is Cell and Gene Therapy going?
- News
NanoPhoria Bioscience awarded €17.5 M from European Innovation Council’s accelerator program
- News
TISSIUM strengthens executive leadership team with key appointments
- News
Latent Labs secures $50M in funding to realize the potential of AI-powered, programmable biology
- News
RefleXion expands access to SCINTIX therapy with first freestanding cancer center
- News
BrightHeart unveils breakthrough AI results at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, revolutionizing prenatal care
- News
Amid the buzz at JP Morgan conference, Sofinnova Partners' Antoine Papiernik is optimistic
- News
Mainstay Medical announces positive outcomes from landmark RESTORE clinical trial of ReActiv8®
- News
Bioptimus hits $76M funding milestone and prepares to launch groundbreaking foundation model for biology
- News
Mediar Therapeutics enters into global licensing agreement with Lilly to advance first-in-class WISP1 antibody for the treatment of idiopathic pulmonary fibrosis (IPF)
- News
Global debut in an ASC setting at Surgeon's Point Surgery Center for Moon Surgical's Maestro System
- News
Tenpoint Therapeutics announces positive topline data from Phase 3 pivotal study, BRIO-II, of BRIMOCHOL™ PF for the treatment of presbyopia